Thermoluminescence dosimetry for in-vivo verification of high dose rate brachytherapy for prostate cancer

  • R. Das
  • W. Toye
  • T. Kron
  • S. Williams
  • G. Duchesne
Scientific Papers


It was the aim of the study to verify dose delivered in urethra and rectum during High Dose Rate brachytherapy boost (HDRBB) of prostate cancer patients. During the first fraction of HDRBB measurement catheters were placed in the urethra and rectum of prostate cancer patients. These contained LiF:Mg,Ti Thermoluminescence Dosimetry (TLD) rods of 1mm diameter, with up to 11 detectors positioned every 16 mm separated by radio-opaque markers. A Lorentzian peak function was used to fit the data. Measurements from 50 patients were evaluated and measured doses were compared with predictions from the treatment planning system (Plato Vs 13.5 to 14.1). Prospective urinary and rectal toxicity scores were collected following treatment. In more than 90% of cases, the Lorentzian peak function provided a good fit to both experimental and planning urethral data (r2 > 0.9). In general there was good agreement between measured and predicted doses with the average difference between measured and planned maximum dose being 0.1Gy. No significant association between dose and any clinical endpoints was observed in 43 patients available for clinical evaluation. An average inferior shift of 2 mm between the plan and the measurement performed approximately 1 hour after the planning CT scan was found for the dose distribution in the cohort of patients for the urethra measurements. Rectal measurements proved to be more difficult to interpret as there is more variability of TLD position between planning and treatment. TLD in-vivo measurements are easily performed in urethra and rectum during HDR brachytherapy of prostate patients. They verify the delivery and provide information about the dose delivered to critical structures. The latter may be of particular interest if higher doses are to be given per fraction such as in HDR monotherapy.

Key words

HDR brachytherapy prostate cancer in-vivo dosimetry TLD treatment planning rectum dose urethra dose 


  1. 1.
    Martinez, A.A., Pataki, I., Edmundson, G., et al.Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys 49: 61–69, 2001.PubMedGoogle Scholar
  2. 2.
    Morton, G.C.The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol) 17: 219–227, 2005.Google Scholar
  3. 3.
    Khoo, V.S.,Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 17: 560–571, 2005.Google Scholar
  4. 4.
    Chin, Y.S., Bullard, J., Bryant, L., et al.,High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol) 18: 474–479, 2006.Google Scholar
  5. 5.
    Pinkawa, M., Fischedick, K., Treusacher, P., et al.,Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer—a phase II study. Radiother Oncol 78: 41–46, 2006.CrossRefPubMedGoogle Scholar
  6. 6.
    Duchesne, G.M. and Peters, L.J.,What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44: 747–748, 1999.PubMedGoogle Scholar
  7. 7.
    Fowler, J.F.,The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44: 265–276, 2005.CrossRefPubMedGoogle Scholar
  8. 8.
    Yoshioka, Y., Nose, T., Yoshida, K., et al.,High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity. Int J Radiat Oncol Biol Phys 56: 213–220, 2003.PubMedGoogle Scholar
  9. 9.
    Grills, I.S., Martinez, A.A., Hollander, M., et al.,High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171: 1098–1104, 2004.CrossRefPubMedGoogle Scholar
  10. 10.
    Hoskin, P.J., Bownes, P.J., Ostler, P., et al.High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 68: 285–288, 2003.CrossRefPubMedGoogle Scholar
  11. 11.
    Mullokandov, E. and Gejerman, G.,Analysis of serial CT scans to assess template and catheter movement in prostate HDR brachytherapy. Int J Radiat Oncol Biol Phys 58: 1063–1071, 2004.PubMedGoogle Scholar
  12. 12.
    Brezovich, I.A., Duan, J., Pareek, P.N., et al.,In vivo urethral dose measurements: a method to verify high dose rate prostate treatments. Med Phys 27: 2297–2301, 2000.CrossRefPubMedGoogle Scholar
  13. 13.
    Hood, C., Duggan, L., Bazley, S., et al.,LiF:Mg,Cu,P ‘pin worms’: miniature detectors for brachytherapy dosimetry. Radiat Prot Dosimetry 101: 407–410, 2002.PubMedGoogle Scholar
  14. 14.
    Anagnostopoulos, G., Baltas, D., Geretschlaeger, A., et al.,In-vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 57: 1183–1191, 2003.PubMedGoogle Scholar
  15. 15.
    Ghilezan, M., Jaffray, D., Siewerdsen, J., et al.,Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys 62: 406–417, 2005.PubMedGoogle Scholar
  16. 16.
    Feist, H.,Influence of regenerating and evaluation procedures on the supralinear behavior of LiF thermoluminescent dosimeters. Strahlenther.Onkol 164: 223–227, 1988 (in German).PubMedGoogle Scholar
  17. 17.
    Waldhausl, C., Wambersie, A., Potter, R. and Georg, D.,In-vivo dosimetry for gynaecological brachytherapy: physical and clinical considerations. Radiother Oncol 77: 310–317, 2005.CrossRefPubMedGoogle Scholar
  18. 18.
    Kron, T., Duggan, L., Smith, T., et al.,Dose response of various radiation detectors to synchrotron radiation. Phys.Med.Biol 43: 3235–3259, 1998.CrossRefPubMedGoogle Scholar
  19. 19.
    Duggan, L., Hood, C., Warren-Forward, H., et al.,Variations in dose response with x-ray energy of LiF:Mg,Cu,P thermoluminescence dosimeters: implications for clinical dosimetry. Phys.Med.Biol 49: 3831–3845, 2004.CrossRefPubMedGoogle Scholar
  20. 20.
    Kron, T.,Thermoluminescence dosimetry and its applications in medicine—Part 1: Physics, materials and equipment. Australas Phys Eng Sci Med 17: 175–199, 1994.PubMedGoogle Scholar
  21. 21.
    Lee, W.R., deGuzman, A.F., Bare, R.L., et al.Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 46: 83–88, 2000.CrossRefPubMedGoogle Scholar
  22. 22.
    Keyes, M., Schellenberg, D., Moravan, V., et al.,Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys 64: 825–834, 2006.PubMedGoogle Scholar
  23. 23.
    Kapp, K.S., Stuecklschweiger, G.F., Kapp, D.S. and Hackl, A.G.Dosimetry of intracavitary placements for uterine and cervical carcinoma: results of orthogonal film, TLD, and CT-assisted techniques. Radiother Oncol 24: 137–146, 1992.CrossRefPubMedGoogle Scholar
  24. 24.
    Alecu, R., and Alecu, M.,In-vivo rectal dose measurements with diodes to avoid misadministrations during intracavitary high dose rate brachytherapy for carcinoma of the cervix. Med Phys 26: 768–770, 1999.CrossRefPubMedGoogle Scholar

Copyright information

© Australasian College of Physical Scientists and Engineers in Medicine 2007

Authors and Affiliations

  • R. Das
    • 4
  • W. Toye
    • 1
    • 2
  • T. Kron
    • 4
    • 1
  • S. Williams
    • 4
  • G. Duchesne
    • 4
    • 3
  1. 1.Department of Applied PhysicsRMIT UniversityMelbourneAustralia
  2. 2.Radiation Oncology VictoriaMelbourneAustralia
  3. 3.School of Medicine and Health SciencesUniversity of MelbourneMelbourneAustralia
  4. 4.Department of Physical SciencesPeter MacCallum Cancer CentreEast MelbourneAustralia

Personalised recommendations